Post: DP Clinical Congratulates Spectral AI as they Received FDA De Novo Clearance for DeepView® System
We are proud to celebrate a major milestone for our client, Spectral AI, following the FDA’s De Novo clearance of its DeepView® System, an innovative AI-powered imaging technology designed to support burn wound assessment and treatment decisions.
This achievement represents years of research, clinical validation, and collaboration to bring novel technology to clinicians and patients. The FDA’s authorization enables Spectral AI to begin commercial distribution of the DeepView® System in the United States, expanding access to a tool that has the potential to enhance decision-making in burn care settings.
Our team was honored to support Spectral AI throughout the pivotal validation study and additional supporting studies that formed a key component of the FDA submission. We partnered closely with the company on study design, statistical strategy and analyses, and regulatory interactions with the FDA, helping generate the clinical evidence needed to support this important milestone.
At DP Clinical, we are passionate about helping innovative medical device companies navigate complex clinical and regulatory pathways. Spectral AI success reflects the power of strong science, strategic collaboration, and a shared commitment to improving patient care.
Congratulations to the entire Spectral AI team on this significant achievement. We are grateful to have been part of the journey and look forward to seeing the impact the DeepView® System will have on burn care across the United States.